Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan plc (NYSE: ACT) today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego.

Allergan will present data from studies further evaluating: the burden and characteristics of infections caused by resistant Gram-negative pathogens and the antimicrobial activity of AVYCAZ^™ (ceftazidime and avibactam) against certain Gram-negative isolates; efficacy of a single dose of DALVANCE^® (dalbavancin) in the treatment of acute bacterial skin and skin structure infections (ABSSSI), the pharmacodynamic activity of DALVANCE and factors influencing admission/re-admission of patients with ABSSSI; the antimicrobial activity of TEFLARO^® (ceftaroline fosamil) and outcomes for patients with ABSSSI, community-acquired bacterial pneumonia (CABP), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) treated with TEFLARO.

"The data presented at IDWeek demonstrates Allergan's commitment to enhancing patient care and outcomes for areas of greatest medical need," said David Melnick, Vice President, Clinical Development, Anti-Infectives, Allergan. "Allergan is committed to providing access to a portfolio of much-needed therapies designed to address the biggest challenges facing the ID community today."

The scheduled times and titles of the presentations are as follows:

AVYCAZ™ (ceftazidime and avibactam)

Thursday, October 8, 12:30 p.m. – 2:00 p.m.

• Patterns of empiric antibiotic therapy among hospitalized patients with complicated intra-abdominal infections (cIAI) or complicated urinary tract infections (cUTI) due to enterobacteriaceae (poster 160)

Friday, October 9, 12:30 p.m. – 2:00 p.m.

• Antimicrobial activity of ceftazidime-avibactam and comparator agents tested against certain Gram-negative organisms isolated from urinary tract infections (UTI): results from the International Network for Optimal Resistance Monitoring (INFORM) program (poster 777)

Saturday, October 10, 12:30 p.m. – 2:00 p.m.

• Distribution of Gram-Negative Pathogens and Carbapenem Resistance Patterns across United States Hospitals: Will Klebsiella become the new Pseudomonas? (poster 1788)
• Relationship between cumulative number of prior antibiotic exposures and carbapenem resistance among patients with hospital-onset infections due to enterobacteriaceae spp (poster 1793)
• Clinical and economic burden of hospitalized patients with serious infections due to carbapenem resistant enterobacteriaceae (CRE) (poster 1835)

DALVANCE^® (dalbavancin)

Friday, October 9, 12:30 p.m. – 2:00 p.m.

• Single dose treatment with dalbavancin for acute bacterial skin and skin structure infection (poster 785)
• Pharmacodynamic (PD) activity of dalbavancin against VISA Staphylococcus aureus (SA) isolates in the neutropenic murine thigh infection model (poster 798)

Saturday, October 10, 12:30 p.m. – 2:00 p.m.

• Patient factors that influence the decision to admit or discharge patients with acute bacterial skin and skin structure infections (ABSSSI) (poster 1536)
• Factors driving emergency department revisits or hospitalization within 30 days post-discharge (DC) in patients with acute bacterial skin and skin structure infections (ABSSSI) (poster 1537)

TEFLARO^® (ceftaroline fosamil)

Friday, October 9, 12:30 p.m. – 2:00 p.m.

• Comparative evaluation of the antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant S. aureus (MRSA) from USA hospitals by site of infection: results from the ceftaroline surveillance program AWARE (2012-2014) (poster 1118)

Saturday, October 10, 12:30 p.m. – 2:00 p.m.

• Antimicrobial activity of ceftaroline and comparator agents tested against bacterial organisms causing bacteremia in patients with skin and skin structure infections (SSSI) in United States (USA) medical centers (2008-2014) (poster 1543)
• Location of care and ceftaroline fosamil use for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP): CAPTURE study experience (poster 1544)
• Ceftaroline fosamil for the treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP): CAPTURE study experience (poster 1817)